Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evommune, Inc.EVMN · Entity 5539 | Director · 10% owner | February 17, 2026 | February 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evommune, Inc.
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,288,313 |
Reported balance
After 2026-02-17 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 358,680 · Balance 5,288,313 F1: Securities held of record by LSP 7 Cooperatief UA ("LSP 7"). LSP 7 Management B.V. is the sole director of LSP 7. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. As such, LSP 7 Management B.V., Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be deemed to share beneficial ownership of the shares of Common Stock held by LSP 7. Each of Mr. Kleijwegt, Mr. Kuijten and Mr. Rothe disclaims beneficial ownership of such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities held of record by LSP 7 Cooperatief UA ("LSP 7"). LSP 7 Management B.V. is the sole director of LSP 7. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. As such, LSP 7 Management B.V., Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be deemed to share beneficial ownership of the shares of Common Stock held by LSP 7. Each of Mr. Kleijwegt, Mr. Kuijten and Mr. Rothe disclaims beneficial ownership of such shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2026 Filed Feb 19, 2026 21:30 UTC | Evommune, Inc. EVMN · Entity 5539 | GrantCommon Stock | 358,680 | $27.88 | $9,999,998.40 |
DisclosureSEC source: 0001193125-26-059500 · ownership.xml · nonDerivative · entry 1 LSP 7 Cooperative UA · CIK 0001876264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,288,313 F1 · ownership.nature: Securities held of record by LSP 7 Cooperatief UA ("LSP 7"). LSP 7 Management B.V. is the sole director of LSP 7. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. As such, LSP 7 Management B.V., Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be deemed to share beneficial ownership of the shares of Common Stock held by LSP 7. Each of Mr. Kleijwegt, Mr. Kuijten and Mr. Rothe disclaims beneficial ownership of such shares. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:25 UTC | Evommune, Inc. EVMN · Entity 5539 | ConversionSeries C Preferred Stock · Derivative | 6,585,011 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001876264-25-000006 · form4-11122025_091112.xml · derivative · entry 5 LSP 7 Cooperative UA · CIK 0001876264 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 773,069 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date. F3 · price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date. F3 · derivative.exercise_date: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date. F3 · derivative.expiration_date: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date. F4 · ownership.direct: The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:25 UTC | Evommune, Inc. EVMN · Entity 5539 | ConversionSeries B Preferred Stock · Derivative | 5,090,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001876264-25-000006 · form4-11122025_091112.xml · derivative · entry 4 LSP 7 Cooperative UA · CIK 0001876264 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 646,587 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F2 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F2 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F2 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F4 · ownership.direct: The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:25 UTC | Evommune, Inc. EVMN · Entity 5539 | ConversionSeries A Preferred Stock · Derivative | 15,493,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001876264-25-000006 · form4-11122025_091112.xml · derivative · entry 3 LSP 7 Cooperative UA · CIK 0001876264 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,947,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date. F1 · price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date. F4 · ownership.direct: The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:25 UTC | Evommune, Inc. EVMN · Entity 5539 | PurchaseCommon Stock | 1,562,500 | $16.00 | $25,000,000.00 |
DisclosureSEC source: 0001876264-25-000006 · form4-11122025_091112.xml · nonDerivative · entry 2 LSP 7 Cooperative UA · CIK 0001876264 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,929,633 F4 · ownership.direct: The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:25 UTC | Evommune, Inc. EVMN · Entity 5539 | ConversionCommon Stock | 3,367,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001876264-25-000006 · form4-11122025_091112.xml · nonDerivative · entry 1 LSP 7 Cooperative UA · CIK 0001876264 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,367,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date. F2 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F3 · price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date. F4 · ownership.direct: The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.